logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Editas Medicine, Inc.

EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIā€¦ read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$3.03

Price

+2.37%

$0.07

$2.96

Previous Close

$3.05

Open

Premium

52w Discount
Market Cap

$272.458m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$35.836m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$251.231m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$3.04

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$62.420m

$263.652m

Assets

$201.232m

Liabilities

$31.133m

Debt
Debt to Assets

11.8%

-0.1x

Debt to EBITDA
Free Cash Flow

-$215.280m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.